Fleqsuvy (Baclofen) Patent Expiration, LOE Window & CMS Spending

Fleqsuvy (Baclofen) by Azurity: FDA Orange Book LOE 2037-09-29, 1 AB generics, $10.4M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN215602 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2037-09-29
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$10.4M
2024 Medicare Part D Spend$385K
2024 Medicaid Spend$10.0M
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 19.9% 2-yr change)